BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Mutations of the BRAF gene in human cancer

2002 • 10,249 citations

Cell Signaling by Receptor Tyrosine Kinases

2010 • 7,477 citations

Cell Signaling by Receptor Tyrosine Kinases

2000 • 3,570 citations

A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

2003 • 2,723 citations

Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

2004 • 2,674 citations

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

2003 • 1,939 citations

High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

2003 • 1,490 citations

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

2003 • 1,236 citations

RAF/RAS oncogenes and mismatch-repair status

2002 • 1,205 citations

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

2003 • 1,172 citations

MAP kinase kinase kinase, MAP kinase kinase and MAP kinase

1994 • 1,005 citations

Tumor Regression by Targeted Gene Delivery to the Neovasculature

2002 • 848 citations

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

2000 • 848 citations

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

2002 • 784 citations

Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.

2002 • 432 citations

Discovery of a novel Raf kinase inhibitor.

2001 • 417 citations

Suppression of BRAF(V599E) in human melanoma abrogates transformation.

2003 • 412 citations

V599EB-RAF is an Oncogene in Melanocytes

2004 • 343 citations

Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli

2003 • 334 citations

MEK kinase activity is not necessary for Raf-1 function

2001 • 308 citations

Endothelial apoptosis in Braf-deficient mice

1997 • 291 citations

BAY 43-9006: Preclinical Data

2002 • 289 citations

Vascular Endothelial Growth Factor Induction of the Angiogenic Phenotype Requires Ras Activation

2001 • 261 citations

Receptor tyrosine kinases as targets for anticancer drugs

2002 • 251 citations

New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis

2000 • 214 citations

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’)

2002 • 157 citations

Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents

2003 • 126 citations

Mouse Erk-1 gene product is a serine/threonine protein kinase that has the potential to phosphorylate tyrosine.

1991 • 113 citations

VEGF Stimulates MAPK through a Pathway That Is Unique for Receptor Tyrosine Kinases

1999 • 102 citations

Angiozyme: A Novel angiogenesis inhibitor

2001 • 101 citations

Regulation of the Nonreceptor Tyrosine Kinase Brk by Autophosphorylation and by Autoinhibition

2002 • 93 citations

Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention

2002 • 92 citations

Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).

2003 • 82 citations

Inducible gene deletion reveals different roles for B-Raf and Raf-1 in B-cell antigen receptor signalling

2002 • 77 citations

A strategy for the design of multiplex inhibitors for kinase-mediated signalling in angiogenesis

2002 • 55 citations

Inhibition of BRAF activity by the Raf kinase inhibitor BAY 43-9006 inhibits melanoma tumor development

2004 • 1 citations